Navigation Links
Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
Date:6/25/2009

emonstrated a safety profile consistent with previous studies of IPLEX(TM).

Based on the metabolic improvements observed in patients treated with IPLEX(TM) in this trial, and discussions with key opinion leaders, the Company intends to apply for a grant from the Muscular Dystrophy Association ("MDA") to facilitate an additional Phase II trial focused solely on a subset of MMD patients with severe insulin resistance who, based on the results of this trial, may be more likely to benefit from IPLEX(TM) treatment. Alternative methods of assessing muscle function will be considered for the proposed trial.

Dr. Melvin Sharoky, Insmed's Chairman, commented, "We are disappointed that this trial did not meet the majority of its functional endpoints. However, the statistically significant improvement in insulin sensitivity seen in this study suggests that an additional phase II study in MMD patients with severe insulin resistance may be warranted. We appreciate the MDA's financial support for the completed trial and look forward to the possibility of continuing to work with them."

Sharon Hesterlee, Senior Vice President and Executive Director of MDA Venture Philanthropy, said, "While the phase II clinical trial of IPLEX(TM) did not show efficacy in the overall MMD population in this trial, based on the data generated, we look forward to evaluating Insmed's grant application for a possible Phase II trial aimed at MMD patients with severe insulin resistance."

Dr. Sharoky continued, "IPLEX(TM) continues to demonstrate a strong safety profile and we believe it offers a potential treatment in multiple therapeutic areas, including Amyotrophic Lateral Sclerosis. Beyond IPLEX(TM), our current cash reserves of approximately $120 million provides us with a significant opportunity to continue growing our business through a variety of potential business development initiatives. We look forward to continuing to exp
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed CEO Resigns Due to Health Concerns
2. Insmed Announces First Quarter 2009 Financial Results
3. Insmed Regains NASDAQ Compliance
4. Insmed to Host First Quarter 2009 Conference Call
5. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
6. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
7. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
8. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
9. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
10. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
11. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Dr. Williams says, “Find ... on healthcare offers a three phase process that can ... delivery system that would go far beyond anything previously ... the delivery of healthcare.” , “Every effort to improve ... to provide discernable progress throughout that system because all ...
(Date:9/23/2014)... 23, 2014 New spin-out ... Innovations, Cambridge Innovation Capital and Johnson & Johnson ... genomics company focused on harnessing the potential of ... testing and treatment, today announced it has raised ... Innovations and including Cambridge Innovation Capital and Johnson ...
(Date:9/22/2014)... SANTA CLARA, Calif. , Sept. 22, ... WBMD ), the leading source of health information, today ... that provide novel insights regarding physician and patient ... care.  Dr. Eric Topol , a leading authority ... serves as both Editor-in-Chief of Medscape and Chief Academic ...
(Date:9/22/2014)... cell fragments whose job it is to stop bleeding, ... But they can "feel" the physical environment around them, ... Platelets respond to surfaces with greater stiffness by increasing ... other platelets and other components of the clotting system, ... give them credit for, in that they are able ...
Breaking Biology Technology:Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Platelets modulate clotting behavior by 'feeling' their surroundings 2
... Genetic Test Provides Early Diagnosis of Mitochondrial Diseases ... MEDomics, LLC ( www.medomics.com ) announces ... diseases, a group of disorders that can result ... headaches, blindness, deafness, and diabetes. The MEDomics mitochondrial ...
... Caliper Life Sciences, Inc. (Nasdaq: CALP ) today ... House entitled, "Innovation for Experimentation" to be held June 17, ... the Investor Breakout Session from 2:30 - 4:00 p.m. EDT. ... feature presentations by Kevin Hrusovsky, President and CEO, as well ...
... N.J., June 8 A study in ... , published by Elsevier, demonstrates that the Hepascore(TM) liver ... diagnose and stage liver fibrosis in patients with chronic ... biopsy, the standard of care for staging fibrosis, in ...
Cached Biology Technology:MEDomics Announces MitoDx(TM), the First NextGen Mitochondrial Genome Diagnostic Test 2MEDomics Announces MitoDx(TM), the First NextGen Mitochondrial Genome Diagnostic Test 3Caliper Life Sciences to Webcast Investor Session of Open House 2Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 2Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 3Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 4
(Date:9/23/2014)... -- Newest Market IPO,s and exchange ... significant investor attention with news concerning shareholder updates and new ... NXT-ID, Inc. (NASDAQ: NXTD ), Alibaba Group Holding ... MBLY ), GoPro, Inc. (NASDAQ: GPRO ) ... (NASDAQ: NXTD ) recently completed an essential round ...
(Date:9/23/2014)... parasitic DNA fragments called "jumping genes" that insert themselves ... And that phenomenon can result in age-related diseases such ... now report that the "jumping genes" in mice become ... stops keeping them in check in order to take ... today in Nature Communications , Professor of Biology ...
(Date:9/22/2014)... September 23, 2014 A new American Cancer Society ... Assistance Program (SNAP), previously known as the food ... with income eligible non-participants. The authors say the ... at enhancing the dietary quality of SNAP participants. ... individuals and households with the resources to obtain ...
Breaking Biology News(10 mins):Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7A multi-function protein is key to stopping genomic parasites from 'jumping' 2Federal food program puts food on the table, but dietary quality could be improved 2
... Calif., June 6 Communication,Intelligence Corporation (the "Company") ... signature solutions for business process,automation in the financial ... announced today that it has closed a financing, ... LLC (the "Investor")., As part of the ...
... basic questions about how life originated and has ... Foundation,s (NSF) Division of Environmental Biology (DEB). Ranging ... NSF,s awards for these studies will help resolve ... responses to environmental changes, including climate change. ...
... it was black as night. It was May 19, 1780 ... at hand. Accounts of that day, which became known as ... candlelight, night birds coming out to sing, flowers folding their ... has been solved by researchers at the University of Missouri ...
Cached Biology News:Communication Intelligence Corporation Closes $3.6 Million Financing 2Communication Intelligence Corporation Closes $3.6 Million Financing 3Communication Intelligence Corporation Closes $3.6 Million Financing 4National Science Foundation funds research addressing enduring questions of life 2National Science Foundation funds research addressing enduring questions of life 3National Science Foundation funds research addressing enduring questions of life 4Mystery of infamous 'New England Dark Day' solved by 3 rings 2